Supporting Information

Efficient approach for the design of effective chiral quaternary phosphonium salts in asymmetric conjugate additions

Seiji Shirakawa, Atsuyuki Kasai, Takashi Tokuda and Keiji Maruoka*

Laboratory of Synthetic Organic Chemistry and Special Laboratory of Organocatalytic Chemistry Department of Chemistry, Graduate School of Science, Kyoto University, Sakyo, Kyoto 606-8502, Japan

General Information

¹H NMR spectra were measured on a JEOL JNM-FX 400 NMR instrument (400 MHz for ¹H NMR). ¹³C NMR spectra were measured on JEOL JNM-FX 400 NMR and JEOL JNM-ECA 500 NMR instruments (100 and 125 MHz for ¹³C NMR). ³¹P NMR spectra were measured on a JEOL JNM-ECA 500 NMR instrument (200 MHz for ³¹P NMR). Tetramethylsilane (TMS) served as the internal standard (0 ppm) for ¹H NMR, and CDCl₃ served as the internal standard (77.0 ppm) for ¹³C NMR. The following abbreviations were used to express the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad. High performance liquid chromatography (HPLC) was performed on Shimadzu 10A instruments using Daicel Chiralpak AD-H, AD-3, or Chiralcel OD-H (4.6 mm × 250 mm) columns. High-resolution mass spectra (HRMS) were performed on BRUKER microTOF focus-KR. Optical rotations were measured on a JASCO DIP-1000 digital polarimeter. All reactions were monitored by thin-layer chromatography carried out on Merck precoated TLC plates (silica gel 60GF-254, 0.25 mm), visualization by using UV (254 nm), or dyes such as KMnO₄. The products were purified by flash column chromatography on silica gel 60N [Kanto Chemical Co., Inc. (spherical, neutral)] or Merck preparative thin layer chromatography on silica gel (PLC 60 F254, 0.5 mm). All simple chemicals were purchased and used as received.

Experimental Section

General Procedure for the Synthesis of Chiral Phosphonium Salts 9.

A solution of (*S*)-OH-MOP¹ (0.05 mmol) and alkyl halide (0.06 mmol) in toluene (1.0 mL) was stirred for 10 h at 110 °C. The mixture was concentrated, and the residue was purified by column chromatography on silica gel (CH₂Cl₂/MeOH = 50:1-10:1 as eluent) to give a phosphonium salt **9** (91–97% yield).



9I: $[\alpha]^{30}{}_{D} = -76.3$ (*c* = 1.00, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 9.74 (s, 1H), 8.74 (d, *J* = 1.2 Hz, 1H), 8.33 (d, *J* = 1.2 Hz, 2H), 7.95–8.15 (m, 2H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.83 (d, *J* = 9.2 Hz, 1H), 7.62–7.78 (m, 5H), 7.53 (d, *J* = 8.8 Hz, 1H), 7.49 (d, *J* = 8.0 Hz, 1H), 7.39–7.46 (m, 1H), 7.32–7.38 (m, 1H), 7.19–7.31 (m, 2H), 7.12–7.19 (m, 1H), 6.93–7.10 (m, 2H),

6.71–6.89 (m, 3H), 6.63 (d, J = 8.0 Hz, 1H), 6.17–6.48 (m, 1H), 4.75–5.05 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 153.9, 147.7 (d, $J_{C-P} = 3.3$ Hz), 147.4 (d, $J_{C-P} = 9.1$ Hz), 135.8 (d, $J_{C-P} = 2.5$ Hz), 134.7 (d, $J_{C-P} = 2.5$ Hz), 134.0, 133.9, 133.5 (d, $J_{C-P} = 9.9$ Hz), 133.3, 133.2 (d, $J_{C-P} = 7.4$ Hz), 132.3 (d, $J_{C-P} = 3.3$ Hz), 131.8, 131.7 (d, $J_{C-P} = 4.9$ Hz), 130.9 (d, $J_{C-P} = 10.7$ Hz), 130.5, 130.4 (d, $J_{C-P} = 13.1$ Hz), 128.5, 128.3, 128.1, 128.0, 127.9, 127.8, 127.5, 126.8, 123.9, 123.2, 119.6, 119.1 (d, $J_{C-P} = 86.4$ Hz), 117.8, 117.4 (d, $J_{C-P} = 89.7$ Hz), 115.1, 115.0, 112.7 (d, $J_{C-P} = 88.1$ Hz), 27.5 (d, $J_{C-P} = 48.6$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.6; HRMS (ESI-TOF) calcd for C₃₉H₂₈N₂O₅P⁺: 635.1730 ([M]⁺), found 635.1730.

9a: $[\alpha]^{29}_{D} = -28.3$ (c = 1.04, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 10.04 (s, 1H), 7.99 (d, J = 9.6 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), r.62-7.81 (m, 5H), 7.50–7.61 (m, 4H), 7.30–7.41 (m, 2H), 7.12–7.24 (m, 5H), 7.00–7.11 (m, 3H), 6.91–6.99 (m, 2H), 6.81–6.91 (m, 3H), 6.65–6.72 (m, 1H), 5.28 (dd, J = 14.4, 14.4 Hz, 1H), 3.84 (dd, J = 13.2, 14.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 154.3, 146.1 (d, $J_{C-P} = 9.9$ Hz), 135.4 (d, $J_{C-P} = 2.4$ Hz), 134.1 (d, $J_{C-P} = 2.5$ Hz), 133.7, 133.54, 133.50, 133.3 (d, $J_{C-P} = 9.1$ Hz), 132.8 (d, $J_{C-P} = 3.3$ Hz), 131.9 (d, $J_{C-P} = 9.8$ Hz), 131.3, 131.2 (d, $J_{C-P} = 5.7$ Hz), 129.9, 129.8 (d, $J_{C-P} = 12.4$ Hz), 128.6, 128.5 (d, $J_{C-P} = 13.2$ Hz), 128.3, 128.2 (d, $J_{C-P} = 3.3$ Hz), 127.95, 127.75, 127.73 (d, $J_{C-P} = 12.3$ Hz), 127.5, 126.9 (d, $J_{C-P} = 9.0$ Hz), 126.7, 123.7, 122.9, 119.8 (d, $J_{C-P} = 87.3$ Hz), 119.6, 118.6 (d, $J_{C-P} = 85.6$ Hz), 114.74, 114.68, 114.2 (d, $J_{C-P} = 87.2$ Hz), 29.2 (d, $J_{C-P} = 46.9$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.0; HRMS (ESI-TOF) calcd for C₃₉H₃₀OP⁺: 545.2029 ([M]⁺), found 545.2040.



9b: $[\alpha]^{22}{}_{D} = -16.7 \ (c = 1.00, \text{ CHCl}_3); {}^{1}\text{H} \text{ NMR} \ (400 \text{ MHz}, \text{ CDCl}_3)$ δ 9.98 (s, 1H), 7.95 (d, J = 9.2 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.82 (dd, J = 2.8, 9.0 Hz, 1H), 7.61–7.77 (m, 4H), 7.46–7.61 (m, 4H), 7.31–7.43 (m, 2H), 7.12–7.30 (m, 5H), 7.03–7.11 (m, 2H), 6.90–7.03 (m, 3H), 6.74–6.89 (m, 2H), 6.69 (d, J = 8.4 Hz, 1H), 5.17

(dd, J = 15.4, 15.4 Hz, 1H), 4.10 (dd, J = 13.8, 14.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 160.6 (dd, $J_{C-P} = 6.2$ Hz, $J_{C-F} = 248.9$ Hz), 154.2, 146.2 (d, $J_{C-P} = 9.0$ Hz), 135.5 (d, $J_{C-P} = 2.5$ Hz), 134.2 (d, $J_{C-P} = 3.3$ Hz), 133.7 (d, $J_{C-P} = 13.2$ Hz), 133.5, 133.39, 133.38, 133.33, 133.30, 133.28, 133.0 (d, $J_{C-P} = 3.3$ Hz), 132.0 (d, $J_{C-P} = 9.8$ Hz), 131.4, 130.4 (dd, $J_{C-P} = 3.3$ Hz, $J_{C-F} = 8.3$ Hz), 130.0, 129.6 (d, $J_{C-P} = 12.3$ Hz), 128.5 (d, $J_{C-P} = 13.1$ Hz), 128.3 (d, $J_{C-P} = 10.7$ Hz), 128.1, 128.0, 127.9, 127.8, 127.6, 126.7, 124.5 (dd, $J_{C-P} = 3.3$ Hz, $J_{C-F} = 3.3$ Hz), 123.6, 122.9, 119.64, 119.55 (d, $J_{C-P} = 86.4$ Hz), 118.3 (d, $J_{C-P} = 85.6$ Hz), 115.3 (dd, $J_{C-P} = 2.9$ Hz, $J_{C-F} = 22.3$ Hz), 114.7 (dd, $J_{C-P} = 8.2$ Hz, $J_{C-F} = 14.8$ Hz), 114.6, 114.5, 114.2 (d, $J_{C-P} = 84.8$ Hz), 23.0 (d, $J_{C-P} = 49.4$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 23.6; HRMS (ESI-TOF) calcd for C₃₉H₂₉FOP⁺: 563.1935 ([M]⁺), found 563.1935.



9c: $[\alpha]^{25}{}_{D} = -30.2$ (*c* = 0.82, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 10.25 (s, 1H), 7.92 (d, *J* = 8.8 Hz, 2H), 7.63–7.85 (m, 5H), 7.56–7.63 (m, 2H), 7.54 (d, *J* = 9.2 Hz, 1H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.29–7.44 (m, 2H), 6.97–7.24 (m, 6H), 6.83–6.95 (m, 4H), 6.74–6.83 (m, 1H), 6.66 (d, *J* = 8.4 Hz, 1H), 6.55–6.63 (m, 1H), 5.49 (dd, *J* = 15.2, 15.2 Hz, 1H), 3.97 (dd, *J* = 13.6, 14.8 Hz, 1H); ¹³C

NMR (100 MHz, CDCl₃) δ 162.2 (dd, $J_{C-P} = 3.7$ Hz, $J_{C-F} = 248.9$ Hz), 154.6, 146.6 (d, $J_{C-P} = 9.0$ Hz), 135.6 (d, $J_{C-P} = 2.5$ Hz), 134.3 (d, $J_{C-P} = 2.5$ Hz), 133.8 (d, $J_{C-P} = 13.2$ Hz), 133.5, 133.4 (d, $J_{C-P} = 9.1$ Hz), 132.6 (d, $J_{C-P} = 3.3$ Hz), 131.6 (d, $J_{C-P} = 9.9$ Hz), 131.5, 130.2 (dd, $J_{C-P} = 3.3$ Hz, $J_{C-F} = 8.2$ Hz), 130.1, 130.0 (d, $J_{C-P} = 12.3$ Hz), 129.6 (dd, $J_{C-P} = 8.2$ Hz, $J_{C-F} = 8.2$ Hz), 128.5 (d, $J_{C-P} = 10.7$ Hz), 128.3 (d, $J_{C-P} = 12.4$ Hz), 128.1, 128.0, 127.8, 127.7, 127.6 (d, $J_{C-P} = 13.2$ Hz), 127.4 (dd, $J_{C-P} = 5.8$ Hz, $J_{C-F} = 3.3$ Hz), 126.6, 123.8, 122.9, 120.2 (d, $J_{C-P} = 87.2$ Hz), 119.9, 118.5 (d, $J_{C-P} = 85.6$ Hz), 118.1 (dd, $J_{C-P} = 5.4$ Hz, $J_{C-F} = 22.7$ Hz), 115.3 (dd, $J_{C-P} = 3.7$ Hz, $J_{C-F} = 21.0$ Hz), 114.84, 114.78, 113.8 (d, $J_{C-P} = 88.1$ Hz), 28.5 (d, $J_{C-P} = 46.9$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.1; HRMS (ESI-TOF) calcd for C₃₉H₂₉FOP⁺: 563.1935 ([M]⁺), found

563.1928.



9d: $[\alpha]^{26}{}_{D} = -31.1 \ (c = 1.00, \text{CHCl}_3); {}^{1}\text{H NMR} \ (400 \text{ MHz}, \text{CDCl}_3)$ $\delta 10.07 \ (s, 1\text{H}), 7.87-8.00 \ (m, 2\text{H}), 7.72-7.84 \ (m, 3\text{H}), 7.56-7.72 \ (m, 4\text{H}), 7.53 \ (d, J = 8.8 \text{ Hz}, 1\text{H}), 7.52 \ (d, J = 7.6 \text{ Hz}, 1\text{H}), 7.28-7.43 \ (m, 2\text{H}), 7.12-7.23 \ (m, 3\text{H}), 7.02-7.12 \ (m, 2\text{H}), 6.91-7.00 \ (m, 2\text{H}), 6.79-6.91 \ (m, 3\text{H}), 6.72 \ (dd, J = 8.4, 8.4 \text{ Hz}, 7.12-7.23 \ (dd, J = 8.4, 8.4 \text{ Hz})$

2H), 6.67 (d, J = 8.0 Hz, 1H), 5.44 (dd, J = 15.2, 15.2 Hz, 1H), 4.00 (dd, J = 13.2, 15.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 162.4 (dd, $J_{C-P} = 4.1$ Hz, $J_{C-F} = 249.4$ Hz), 154.3, 146.4 (d, $J_{C-P} = 9.1$ Hz), 135.5 (d, $J_{C-P} = 2.5$ Hz), 134.2 (d, $J_{C-P} = 2.4$ Hz), 133.7 (d, $J_{C-P} = 13.1$ Hz), 133.43, 133.42 (d, $J_{C-P} = 9.1$ Hz), 133.1 (dd, $J_{C-P} = 5.8$ Hz, $J_{C-F} = 8.3$ Hz), 132.5 (d, $J_{C-P} = 3.3$ Hz), 131.5 (d, $J_{C-P} = 9.9$ Hz), 131.4, 130.0, 129.9, 128.6 (d, $J_{C-P} = 10.6$ Hz), 128.2 (d, $J_{C-P} = 12.4$ Hz), 128.04, 127.96, 127.8, 127.6, 127.5, 126.6, 123.8, 122.93, 122.87 (dd, $J_{C-P} = 8.2$ Hz, $J_{C-F} = 3.3$ Hz), 120.1 (d, $J_{C-P} = 87.3$ Hz), 119.7, 118.5 (d, $J_{C-P} = 88.1$ Hz), 27.9 (d, $J_{C-P} = 46.9$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 23.8; HRMS (ESI-TOF) calcd for C₃₉H₂₉FOP⁺: 563.1935 ([M]⁺), found 563.1931.



9e: $[\alpha]_{D}^{26} = -40.0$ (*c* = 1.01, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 9.97 (s, 1H), 7.93 (d, *J* = 8.4 Hz, 1H), 7.90 (d, *J* = 9.2 Hz, 1H), 7.76–7.86 (m, 2H), 7.58–7.75 (m, 5H), 7.53 (d, *J* = 8.8 Hz, 1H), 7.52 (d, *J* = 6.8 Hz, 1H), 7.35–7.45 (m, 1H), 7.28–7.35 (m, 3H), 7.11–7.24 (m, 5H), 7.01–7.10 (m, 2H), 6.81–6.93 (m,

2H), 6.76 (dd, J = 8.8, 10.8 Hz, 1H), 6.66 (d, J = 8.8 Hz, 1H), 5.72 (dd, J = 15.6, 15.6 Hz, 1H), 4.04–4.26 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.0, 146.4 (d, $J_{C-P} = 8.4$ Hz), 135.4 (d, $J_{C-P} = 2.5$ Hz), 134.2 (d, $J_{C-P} = 2.4$ Hz) 133.6 (d, $J_{C-P} = 13.1$ Hz), 133.4 (d, $J_{C-P} = 8.4$ Hz), 133.3, 132.4 (d, $J_{C-P} = 2.4$ Hz), 131.8 (d, $J_{C-P} = 4.8$ Hz), 131.35, 131.27 (d, $J_{C-P} = 9.5$ Hz), 121.983 (dq, $J_{C-P} = 3.6$ Hz, $J_{C-F} = 32.3$ Hz), 129.978, 129.87, 128.4 (d, $J_{C-P} = 9.5$ Hz), 128.1 (d, $J_{C-P} = 13.1$ Hz), 128.0 (d, $J_{C-P} = 8.4$ Hz), 127.8, 127.7, 127.44, 127.43 (d, $J_{C-P} = 13.1$ Hz), 126.6, 125.2 (m), 123.7, 123.5 (q, $J_{C-F} = 273.3$ Hz), 122.9, 119.7 (d, $J_{C-P} = 86.1$ Hz), 119.4, 118.2 (d, $J_{C-P} = 84.9$ Hz), 114.82, 114.78, 113.5 (d, $J_{C-P} = 88.6$ Hz), 28.2 (d, $J_{C-P} = 46.6$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.1; HRMS (ESI-TOF) calcd for C₄₀H₂₉F₃OP⁺: 613.1903 ([M]⁺), found 613.1893.



9f: $[\alpha]_{D}^{27} = -49.2$ (*c* = 1.03, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 9.98 (s, 1H), 7.97 (d, *J* = 9.2 Hz, 1H), 7.92 (d, *J* = 8.4

Hz, 1H), 7.78 (dd, J = 3.2, 8.8 Hz, 1H), 7.61–7.73 (m, 4H), 7.47–7.61 (m, 4H), 7.29–7.43 (m, 2H), 7.11–7.23 (m, 4H), 7.03–7.10 (m, 1H), 6.88–7.01 (m, 3H), 6.73–6.83 (m, 2H), 6.68 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.4 Hz, 2H), 5.14 (dd, J = 15.0, 15.0 Hz, 1H), 3.79 (dd, J = 12.8, 15.2 Hz, 1H), 3.69 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 159.5 (d, $J_{C-P} = 3.5$ Hz), 154.5, 146.2 (d, $J_{C-P} = 9.5$ Hz), 135.5 (d, $J_{C-P} = 2.4$ Hz), 134.1 (d, $J_{C-P} = 2.4$ Hz), 133.7 (d, $J_{C-P} = 13.1$ Hz), 133.6, 133.5 (d, $J_{C-P} = 8.4$ Hz), 132.7 (d, $J_{C-P} = 2.4$ Hz), 132.5 (d, $J_{C-P} = 6.0$ Hz), 131.9 (d, $J_{C-P} = 9.5$ Hz), 131.4, 130.0, 129.8 (d, $J_{C-P} = 6.0$ Hz), 127.8, 127.69, 127.69 (d, $J_{C-P} = 12.0$ Hz), 126.6, 123.8, 122.9, 120.2 (d, $J_{C-P} = 87.4$ Hz), 118.9 (d, $J_{C-P} = 83.8$ Hz), 118.3 (d, $J_{C-P} = 8.4$ Hz), 114.8 (d, $J_{C-P} = 4.8$ Hz), 114.4 (d, $J_{C-P} = 87.4$ Hz), 114.10, 55.2, 28.5 (d, $J_{C-P} = 46.6$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 23.2; HRMS (ESI-TOF) calcd for C₄₀H₃₂O₂P⁺: 575.2134 ([M]⁺), found 575.2122.



9g: $[\alpha]^{27}{}_{D} = -40.8 \ (c = 0.98, CHCl_3); {}^{1}H NMR \ (400 MHz, CDCl_3)$ $<math>\delta$ 9.90 (s, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.75–7.84 (m, 3H), 7.57–7.75 (m, 4H), 7.52 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.28–7.44 (m, 2H), 7.11–7.25 (m, 3H), 7.00–7.11 (m, 2H), 6.77–6.94 (m, 3H), 6.48–6.73 (m, 4H), 5.66 (dd, J = 15.6, 15.6 Hz, 1H), 4.17 (dd, J = 14.2, 14.2 Hz, 1H); ${}^{13}C$

NMR (100 MHz, CDCl₃) δ 162.3 (ddd, $J_{C-P} = 3.3$ Hz, $J_{C-F} = 12.8$, 250.1 Hz), 154.1, 146.4 (d, $J_{C-P} = 9.1$ Hz), 135.6 (d, $J_{C-P} = 2.5$ Hz), 134.3 (d, $J_{C-P} = 2.4$ Hz), 133.7 (d, $J_{C-P} = 13.2$ Hz), 133.31, 133.30 (d, $J_{C-P} = 9.0$ Hz), 132.5 (d, $J_{C-P} = 2.5$ Hz), 131.5, 131.4, 131.2 (dt, $J_{C-P} = 9.1$ Hz, $J_{C-F} = 9.1$ Hz), 130.1, 129.9, 128.4 (d, $J_{C-P} = 10.7$ Hz), 128.2 (d, $J_{C-P} = 12.3$ Hz), 128.1, 128.0, 127.9, 127.7, 127.6, 127.5, 126.6, 123.8, 123.0, 119.7 (d, $J_{C-P} = 87.2$ Hz), 119.6, 118.1 (d, $J_{C-P} = 85.6$ Hz), 114.81, 114.75, 114.5 (ddd, $J_{C-P} = 6.4$ Hz, $J_{C-F} = 6.4$, 20.3 Hz), 113.4 (d, $J_{C-P} = 88.9$ Hz), 103.6 (dd, $J_{C-P} = 3.3$ Hz, $J_{C-F} = 25.1$ Hz), 28.2 (d, $J_{C-P} = 48.6$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.1; HRMS (ESI-TOF) calcd for C₃₉H₂₈F₂OP⁺: 581.1840 ([M]⁺), found 581.1856.



9h: $[\alpha]_{D}^{29} = -43.3$ (*c* = 1.00, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 9.82 (s, 1H), 7.93 (d, *J* = 8.4 Hz, 1H), 7.79–7.90 (m, 3H), 7.59–7.78 (m, 6H), 7.44–7.58 (m, 4H), 7.37–7.44 (m, 1H), 7.31–7.36 (m, 1H), 7.20–7.31 (m, 2H), 7.12–7.20 (m, 1H), 6.98–7.11 (m, 2H), 6.78–6.96 (m, 2H), 6.72 (dd, *J* = 8.8, 10.8 Hz, 1H), 6.65 (d, *J* = 8.4, 1H), 6.00 (dd, *J* = 15.6, 15.6 Hz, 1H),

4.28–4.55 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 146.9 (d, $J_{C-P} = 9.5$ Hz), 135.7 (d, $J_{C-P} = 2.5$ Hz), 134.4 (d, $J_{C-P} = 2.4$ Hz) 133.8 (d, $J_{C-P} = 13.1$ Hz), 133.4, 133.3, 132.6 (d, $J_{C-P} = 2.4$ Hz), 131.8, 131.5, 131.4 (dq, $J_{C-P} = 2.5$ Hz, $J_{C-F} = 33.5$ Hz), 131.3 (d, $J_{C-P} = 10.8$ Hz), 130.7 (d, $J_{C-P} = 8.4$ Hz), 130.2, 130.1 (d, $J_{C-P} = 12.0$ Hz), 128.27, 128.22, 128.18, 128.12, 128.0, 127.944 (d, $J_{C-P} = 13.1$ Hz), 127.939, 127.8, 127.5, 126.7, 123.8, 123.0, 122.5 (q, $J_{C-F} = 274.1$ Hz), 121.7 (m), 119.8, 119.2 (d, $J_{C-P} = 87.4$ Hz), 117.7 (d, $J_{C-P} = 86.1$ Hz), 114.95, 114.90, 113.0 (d, $J_{C-P} = 88.5$ Hz), 28.3 (d, $J_{C-P} = 47.9$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.4; HRMS (ESI-TOF) calcd for C₄₁H₂₈F₆OP⁺: 681.1776 ([M]⁺), found 681.1753.



9i: $[\alpha]^{22}{}_{D} = -38.8$ (*c* = 1.02, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 10.15 (s, 1H), 7.94 (d, *J* = 9.2 Hz, 1H), 7.91 (d, *J* = 8.4 Hz, 1H), 7.72–7.84 (m, 3H), 7.57–7.72 (m, 4H), 7.55 (d, *J* = 9.2 Hz, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.29–7.44 (m, 2H), 7.02–7.24 (m, 5H), 6.84–6.99 (m, 3H), 6.68 (d, *J* = 8.0 Hz, 1H), 6.24 (q, *J* = 2.4 Hz, 1H), 6.11 (t, *J* = 2.4 Hz, 2H), 5.21 (dd, *J* = 15.0, 15.0

Hz, 1H), 3.86 (dd, J = 13.0, 14.6 Hz, 1H), 3.35 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 160.4 (d, $J_{C-P} = 3.6$ Hz), 154.4, 146.3 (d, $J_{C-P} = 9.6$ Hz), 135.4 (d, $J_{C-P} = 2.4$ Hz), 134.1 (d, $J_{C-P} = 2.4$ Hz), 133.6 (d, $J_{C-P} = 13.1$ Hz), 133.4 (d, $J_{C-P} = 9.6$ Hz), 132.6 (d, $J_{C-P} = 2.4$ Hz), 131.6 (d, $J_{C-P} = 9.6$ Hz), 131.3, 129.9, 129.8 (d, $J_{C-P} = 12.0$ Hz), 128.8 (d, $J_{C-P} = 7.1$ Hz), 128.7 (d, $J_{C-P} = 10.9$ Hz), 128.3, 128.2, 127.94, 127.90, 127.85, 127.7, 127.6, 127.5 (d, $J_{C-P} = 12.3$ Hz), 126.6, 123.7, 122.9, 120.2 (d, $J_{C-P} = 87.4$ Hz), 119.7, 118.6 (d, $J_{C-P} = 83.8$ Hz), 114.83, 114.79, 114.3 (d, $J_{C-P} = 88.6$ Hz), 108.9 (d, $J_{C-P} = 4.9$ Hz), 101.0 (d, $J_{C-P} = 3.5$ Hz), 55.1, 28.9 (d, $J_{C-P} = 46.8$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.1; HRMS (ESI-TOF) calcd for C₄₁H₃₄O₃P⁺: 605.2240 ([M]⁺), found 605.2231.



9j: $[\alpha]^{27}{}_{D} = -40.8$ (*c* = 1.00, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 10.11 (s, 1H), 7.95 (d, *J* = 8.8 Hz, 1H), 7.88 (d, *J* = 8.4 Hz, 1H), 7.74 (dd, *J* = 3.2, 9.2 Hz, 1H), 7.55–7.69 (m, 8H), 7.30–7.42 (m, 2H), 7.18–7.29 (m, 4H), 7.12–7.18 (m, 1H), 6.95–7.10 (m, 3H), 6.87 (dd, *J* = 8.8, 10.8 Hz, 1H), 6.66 (d, *J* = 8.8 Hz, 1H), 6.64 (t, *J* = 2.2 Hz, 2H), 5.01 (dd, *J* = 14.8, 14.8 Hz, 14.8 Hz,

1H), 3.77 (dd, J = 13.2, 14.8 Hz, 1H), 0.99 (s, 18H); ¹³C NMR (125 MHz, CDCl₃) δ 154.5, 151.1 (d, $J_{C-P} = 3.6$ Hz), 146.2 (d, $J_{C-P} = 9.6$ Hz), 135.3 (d, $J_{C-P} = 2.5$ Hz), 133.9 (d, $J_{C-P} = 2.4$ Hz), 133.6, 133.5 (d, $J_{C-P} = 13.3$ Hz), 133.3 (d, $J_{C-P} = 9.6$ Hz),

133.0 (d, $J_{C-P} = 3.5 \text{ Hz}$), 132.3 (d, $J_{C-P} = 9.5 \text{ Hz}$), 131.2, 129.9, 129.4 (d, $J_{C-P} = 11.9 \text{ Hz}$), 128.5 (d, $J_{C-P} = 13.1 \text{ Hz}$), 128.2 (d, $J_{C-P} = 10.8 \text{ Hz}$), 128.0, 127.9, 127.84, 127.77, 127.66, 127.58, 126.6, 125.56 (d, $J_{C-P} = 12.0 \text{ Hz}$), 125.54 (d, $J_{C-P} = 8.4 \text{ Hz}$), 123.6, 122.7, 122.0 (d, $J_{C-P} = 3.6 \text{ Hz}$), 119.8 (d, $J_{C-P} = 87.4 \text{ Hz}$), 119.7, 118.7 (d, $J_{C-P} = 84.9 \text{ Hz}$), 114.6 (d, $J_{C-P} = 87.4 \text{ Hz}$), 114.52, 114.49, 34.4, 30.9, 30.2 (d, $J_{C-P} = 46.6 \text{ Hz}$); ³¹P NMR (200 MHz, CDCl₃) δ 23.6; HRMS (ESI-TOF) calcd for C₄₇H₄₆OP⁺: 657.3281 ([M]⁺), found 657.3263.



9k: $[\alpha]_{D}^{26} = -57.4$ (*c* = 1.00, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 10.01 (s, 1H), 7.96 (d, *J* = 9.6 Hz, 1H), 7.72–7.87 (m, 3H), 7.61–7.71 (m, 4H), 7.47–7.61 (m, 4H), 7.34–7.44 (m, 2H), 7.20–7.34 (m, 8H), 7.02–7.20 (m, 9H), 6.86–7.02 (m, 3H), 6.70 (d, *J* = 8.4 Hz, 1H), 5.49 (dd, *J* = 14.4, 14.4 Hz, 1H), 3.90–4.20 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.4, 146.5 (d, *J*_{C-P} = 8.4

Hz), 141.7 (d, $J_{C-P} = 2.4$ Hz), 139.4, 135.5, 134.1 (d, $J_{C-P} = 2.4$ Hz), 133.6 (d, $J_{C-P} = 13.1$ Hz), 133.5, 133.4 (d, $J_{C-P} = 9.5$ Hz), 132.7, 131.8 (d, $J_{C-P} = 9.6$ Hz), 131.3, 129.9, 129.7 (d, $J_{C-P} = 12.0$ Hz), 128.7 (d, $J_{C-P} = 6.0$ Hz), 128.6, 128.4 (d, $J_{C-P} = 13.3$ Hz), 128.1 (d, $J_{C-P} = 8.4$ Hz), 127.9, 127.8, 127.7, 127.6, 127.5, 126.6, 125.3 (d, $J_{C-P} = 3.6$ Hz), 123.7, 122.8, 119.8 (d, $J_{C-P} = 86.3$ Hz), 119.7, 118.4 (d, $J_{C-P} = 84.9$ Hz), 114.68, 114.64, 114.1 (d, $J_{C-P} = 87.4$ Hz), 29.3 (d, $J_{C-P} = 47.9$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.1; HRMS (ESI-TOF) calcd for C₅₁H₃₈OP⁺: 697.2655 ([M]⁺), found 697.2630.



9m: $[\alpha]_{D}^{27} = -103.4$ (*c* = 1.01, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 10.41 (s, 1H), 8.00 (d, *J* = 8.8 Hz, 1H), 7.87 (d, *J* = 8.4 Hz, 1H), 7.52–7.81 (m, 9H), 7.29–7.51 (m, 7H), 7.10–7.29 (m, 5H), 7.05 (t, *J* = 7.6 Hz, 1H), 6.89–7.01 (m, 3H), 6.84 (dd, *J* = 9.0, 10.6 Hz, 1H), 6.69 (d, *J* = 8.0 Hz, 1H), 5.41 (dd, *J* = 15.2, 15.2 Hz, 1H), 4.00 (dd, *J* = 13.8, 13.8 Hz, 1H); ¹³C NMR (125 MHz, 1H), 4.00 (dd, *J* = 13.8, 13.8 Hz, 1H); ¹³C NMR (125 MHz, 1H), δ

CDCl₃) δ 154.5, 146.2 (d, $J_{C-P} = 9.5$ Hz), 135.4 (d, $J_{C-P} = 2.5$ Hz), 134.1 (d, $J_{C-P} = 2.5$ Hz), 133.6 (d, $J_{C-P} = 12.0$ Hz), 133.5, 133.4 (d, $J_{C-P} = 9.6$ Hz), 132.72, 132.70, 132.67, 132.64, 132.4 (d, $J_{C-P} = 2.4$ Hz), 131.7 (d, $J_{C-P} = 8.8$ Hz), 131.3, 130.9 (d, $J_{C-P} = 7.1$ Hz), 129.9, 129.7 (d, $J_{C-P} = 11.9$ Hz), 128.6 (d, $J_{C-P} = 10.8$ Hz), 128.4, 128.3, 128.2 (d, $J_{C-P} = 2.4$ Hz), 127.91, 127.88, 127.7, 127.62, 127.59, 127.3, 126.6, 126.4, 126.2, 124.3 (d, $J_{C-P} = 8.4$ Hz), 123.7, 122.8, 119.7 (d, $J_{C-P} = 86.1$ Hz), 119.6, 118.6 (d, $J_{C-P} = 85.0$ Hz), 114.73, 114.69, 114.3 (d, $J_{C-P} = 88.5$ Hz), 29.3 (d, $J_{C-P} = 46.6$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 23.4; HRMS (ESI-TOF) calcd for C₄₃H₃₂OP⁺: 595.2185 ([M]⁺),

found 595.2179.



9n: $[\alpha]^{26}{}_{D} = 116.6 \ (c = 1.02, \text{CHCl}_3); {}^{1}\text{H} \text{NMR} (400 \text{ MHz}, \text{CDCl}_3)$ $\delta 10.61 \ (s, 1\text{H}), 8.23-8.34 \ (m, 2\text{H}), 7.95 \ (d, J = 8.4 \text{ Hz}, 1\text{H}),$ 7.80–7.93 (m, 3H), 7.68–7.80 (m, 5H), 7.66 (d, J = 8.4 \text{ Hz}, 1\text{H}), 7.47–7.62 (m, 2H), 7.35–7.47 (m, 4H), 7.18–7.32 (m, 3H), 7.02–7.18 (m, 3H), 6.42–7.00 (m, 7H), 5.20 (dd, J = 15.0, 15.0 \text{ Hz}, 1\text{H}), 3.81 \ (dd, J = 15.6, 15.6 \text{ Hz}, 1\text{H}); {}^{13}\text{C} \text{ NMR} \ (125 \text{ MHz},

CDCl₃) δ 154.8, 145.7 (d, $J_{C-P} = 7.5$ Hz), 135.1 (d, $J_{C-P} = 2.4$ Hz), 134.1, 134.05, 134.01, 133.9, 133.8, 133.6 (d, $J_{C-P} = 13.3$ Hz), 131.6, 130.8 (d, $J_{C-P} = 5.9$ Hz), 130.6 (d, $J_{C-P} = 4.8$ Hz), 130.2, 129.6 (d, $J_{C-P} = 13.1$ Hz), 129.1 (d, $J_{C-P} = 13.3$ Hz), 128.9, 128.8, 128.5, 128.41, 128.38, 128.29, 128.1, 127.8, 127.2, 126.2, 124.7, 123.8, 123.5, 123.0 (br), 120.4, 120.3 (d, $J_{C-P} = 85.0$ Hz), 118.0 (d, $J_{C-P} = 10.9$ Hz), 117.1 (d, $J_{C-P} = 83.8$ Hz), 116.9 (d, $J_{C-P} = 81.4$ Hz), 115.3, 115.2, 25.0 (d, $J_{C-P} = 44.4$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 23.0; HRMS (ESI-TOF) calcd for C₄₇H₃₄OP⁺: 645.2342 ([M]⁺), found 645.2329.



90: $[\alpha]^{27}{}_{D} = -53.4$ (*c* = 1.00, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 9.93 (s, 1H), 7.89–8.03 (m, 3H), 7.82 (d, *J* = 9.2 Hz, 1H), 7.79 (dd, *J* = 3.2, 9.2 Hz, 1H), 7.58–7.75 (m, 4H), 7.49 (d, *J* = 9.2 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.33–7.41 (m, 1H), 7.28–7.33 (m, 1H), 7.11–7.24 (m, 3H), 7.02–7.10 (m, 1H), 6.95–7.02 (m, 1H),

6.70–6.89 (m, 5H), 6.65 (d, J = 8.4 Hz, 1H), 5.70 (dd, J = 15.4, 15.4 Hz, 1H), 4.51 (dd, J = 14.0, 14.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.0, 151.4 (m), 149.4 (m), 146.6 (d, $J_{C-P} = 9.6$ Hz), 139.3 (dtd, $J_{C-P} = 3.5$ Hz, $J_{C-F} = 15.4$, 255.1 Hz), 135.6 (d, $J_{C-P} = 2.4$ Hz), 134.2 (d, $J_{C-P} = 2.4$ Hz), 133.7 (d, $J_{C-P} = 13.3$ Hz), 133.5 (d, $J_{C-P} = 9.6$ Hz), 133.3, 132.2 (d, $J_{C-P} = 2.5$ Hz), 131.4, 131.1 (d, $J_{C-P} = 9.6$ Hz), 130.08, 130.06 (d, $J_{C-P} = 11.9$ Hz), 128.5 (d, $J_{C-P} = 10.8$ Hz), 128.1, 128.0, 127.9, 127.8 (d, $J_{C-P} = 12.0$ Hz), 127.5, 127.4 (d, $J_{C-P} = 13.3$ Hz), 126.6, 124.1 (m), 123.9, 123.0, 119.9 (d, $J_{C-P} = 83.9$ Hz), 119.5, 118.0 (d, $J_{C-P} = 86.1$ Hz), 115.9 (m), 115.0, 114.9, 113.3 (d, $J_{C-P} = 88.5$ Hz), 27.1 (d, $J_{C-P} = 47.9$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 24.1; HRMS (ESI-TOF) calcd for C₃₉H₂₇F₃OP⁺: 599.1746 ([M]⁺), found 599.1755.



9p: $[\alpha]^{27}_{D} = -10.0 \ (c = 0.99, \text{CHCl}_3); {}^{1}\text{H} \text{ NMR} \ (400 \text{ MHz}, \text{CDCl}_3) \\ \delta 10.11 \ (\text{s}, 1\text{H}), 8.04 \ (\text{dd}, J = 3.0, 9.0 \text{ Hz}, 1\text{H}), 7.99 \ (\text{d}, J = 8.8 \text{ Hz}, 1\text{H}), 7.87 \ (\text{dd}, J = 1.4, 9.0 \text{ Hz}, 1\text{H}), 7.23-7.76 \ (\text{m}, 14\text{H}), 7.09-7.22 \ \text{m}$

(m, 3H), 7.00–7.08 (m, 1H), 6.61 (d, J = 8.8 Hz, 1H), 5.02–5.29 (m, 1H), 3.98 (dd, J = 14.6, 14.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.3, 146.2 (d, $J_{C-P} = 9.5$ Hz), 146.0 (br m), 144.0 (br m), 142.2 (br m), 140.1 (br m), 138.2 (br m), 136.2 (br m), 135.6 (d, $J_{C-P} = 2.4$ Hz), 134.6 (d, $J_{C-P} = 2.4$ Hz), 134.2 (d, $J_{C-P} = 2.4$ Hz), 133.7 (d, $J_{C-P} = 13.3$ Hz), 133.5, 133.3 (d, $J_{C-P} = 10.9$ Hz), 132.8 (d, $J_{C-P} = 10.8$ Hz), 131.5, 130.2, 129.5 (d, $J_{C-P} = 13.1$ Hz), 129.1, 129.0, 128.9, 128.2, 128.1, 128.0, 127.7, 127.5, 127.1 (d, $J_{C-P} = 12.0$ Hz), 126.9, 123.3, 123.0, 119.4, 117.6 (d, $J_{C-P} = 86.1$ Hz), 117.0 (d, $J_{C-P} = 86.3$ Hz), 114.1 (d, $J_{C-P} = 88.6$ Hz), 113.94, 113.89, 103.6 (br m), 20.4 (d, $J_{C-P} = 52.6$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 22.9; HRMS (ESI-TOF) calcd for C₃₉H₂₅F₅OP⁺: 635.1558 ([M]⁺), found 635.1561.

9q: $[\alpha]^{27}_{D} = -3.5$ (*c* = 1.03, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.59 Me ⊕I —PPh₂ (br, 1H), 8.09 (dd, J = 3.0, 9.0 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.91 IΘ (d, J = 9.2 Hz, 1H), 7.59–7.76 (m, 4H), 7.38–7.58 (m, 6H), 7.31–7.38 -ОН (m, 2H), 7.19–7.31 (m, 4H), 7.07–7.18 (m, 1H), 6.83–6.99 (m, 1H), 6.50 (d, J = 8.4 Hz, 1H), 2.31 (d, J = 13.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 153.8, 145.2 (d, $J_{C-P} = 8.4$ Hz), 135.6 (d, $J_{C-P} = 2.4$ Hz), 134.4 (d, $J_{C-P} = 2.4$ Hz), 133.9 (d, $J_{C-P} = 2.4$ Hz), 133.6 (d, $J_{C-P} = 13.1$ Hz), 133.2, 132.3 (d, $J_{C-P} = 9.6$ Hz), 131.9 (d, $J_{C-P} = 10.8$ Hz), 131.4, 130.1, 130.0 (d, $J_{C-P} = 13.1$ Hz), 129.5 (d, $J_{C-P} = 13.1$ Hz), 128.3 (d, $J_{C-P} = 9.6$ Hz), 128.0, 127.8, 127.6 (d, $J_{C-P} = 13.3$ Hz) 127.3, 126.8, 123.6, 123.1, 121.0 (d, $J_{C-P} = 88.6$ Hz), 119.2, 119.0 (d, $J_{C-P} = 88.5$ Hz), 115.9 (d, J_{C-P} = 92.1 Hz), 114.4, 114.3, 11.0 (d, J_{C-P} = 57.4 Hz); ³¹P NMR (200 MHz, CDCl₃) δ 21.0; HRMS (ESI-TOF) calcd for $C_{33}H_{26}OP^+$: 469.1716 ([M]⁺), found 469.1703.

General Procedure for the Synthesis of Bis-Phosphonium Bromides 1–3.

A solution of a chiral bisphosphine (0.05 mmol) and benzyl bromide (0.11 mmol) in toluene (1.0 mL) was stirred for 10 h at 110 °C. The mixture was concentrated, and the residue was purified by column chromatography on silica gel (CH₂Cl₂/MeOH = 50:1-10:1 as eluent) to give a phosphonium salt (89–95% yield).



1: $[\alpha]_{D}^{26} = 12.4$ (*c* = 0.96, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.94–8.06 (m, 4H), 7.83–7.94 (m, 4H), 7.67–7.77 (m, 4H), 7.54–7.65 (m, 8H), 7.15–7.22 (m, 2H), 7.06–7.15 (m, 4H), 6.94–7.04 (m, 4H), 4.64–4.91 (m, 6H), 4.40–4.55 (m, 2H), 3.45–3.66 (m, 2H), 1.17 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 134.4 (d, *J*_{C-P} = 2.4 Hz), 134.2 (d, *J*_{C-P} =

2.4 Hz), 133.5 (d, $J_{C-P} = 14.4$ Hz), 133.4 (d, $J_{C-P} = 14.4$ Hz), 130.2 (d, $J_{C-P} = 6.0$ Hz),

129.3 (d, $J_{C-P} = 9.5$ Hz), 129.2 (d, $J_{C-P} = 8.4$ Hz), 128.3 (d, $J_{C-P} = 3.6$ Hz), 127.7 (d, $J_{C-P} = 3.6$ Hz), 126.5 (d, $J_{C-P} = 8.4$ Hz), 116.58 (d, $J_{C-P} = 85.0$ Hz), 116.55 (d, $J_{C-P} = 83.8$ Hz), 110.6, 74.6 (dd, $J_{C-P} = 5.9$, 15.6 Hz), 30.0 (d, $J_{C-P} = 46.6$ Hz), 26.0, 22.0 (d, $J_{C-P} = 53.9$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 26.0; HRMS (ESI-TOF) calcd for C₄₅H₄₆O₂P₂²⁺: 340.1481 ([M]²⁺), found 340.1470.

2: $[\alpha]^{25}{}_{\rm D}$ = 25.1 (*c* = 0.96, DMSO); ¹H NMR (400 MHz, DMSO-d₆) δ 6.75–7.70 (m, 30H), 2.15–5.45 (br m, 20H); ¹³C NMR (125 MHz, DMSO-d₆) δ 132.1, 131.1, 130.5, 129.3, 129.22, 129.15, 129.10, 128.42, 128.37, 128.2, 127.9, 127.1 (d, *J*_{C-P} = 4.9 Hz), 127.0 (d, *J*_{C-P} = 4.8 Hz),

41.7, 41.6, 41.41, 41.37, 41.2, 41.1, 30.9, 30.3, 25.6 (d, $J_{C-P} = 18.0 \text{ Hz}$), 31P NMR (200 MHz, DMSO-d₆) δ 47.1; HRMS (ESI-TOF) calcd for C₄₈H₅₀P₂²⁺: 344.1688 ([M]²⁺), found 344.1676.

^{Ph} $\stackrel{@}{PPh_2} \stackrel{2Br^{\odot}}{\stackrel{Ph}{Peh_2}}$ **3**: $[\alpha]^{26}_{D} = -59.5 (c = 1.00, CHCl_3)$; ¹H NMR (400 MHz, CDCl_3) δ 9.00–9.15 (m, 1H), 8.30–8.52 (m, 1H), 6.96–7.95 (m, 23H), 6.48–6.94 (m, 9H), 6.05–6.23 (m, 1H), 5.09–5.25 (m, 1H), 4.61–4.81 (m, 1H), 4.36 (br, 1H), 4.20 (s, 5H), 3.95 (s, 1H), 3.38–3.80 (m, 3H), 2.33 (dd, J = 2.6, 18.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl_3) δ 142.2 (d, $J_{C-P} = 7.3$ Hz), 138.6 (d, $J_{C-P} = 7.3$ Hz), 136.7, 136.0 (d, $J_{C-P} = 10.8$ Hz), 135.4, 135.0 (d, $J_{C-P} = 7.3$ Hz), 134.6, 134.4, 133.6, 132.8 (d, $J_{C-P} = 7.1$ Hz), 130.3 (d, $J_{C-P} = 11.9$ Hz), 129.8 (d, $J_{C-P} = 13.3$ Hz), 129.3, 129.1, 129.0, 128.9 (d, $J_{C-P} = 13.1$ Hz), 127.8 (d, $J_{C-P} = 12.0$ Hz), 127.3, 127.0 (d, $J_{C-P} = 8.4$ Hz), 115.4 (d, $J_{C-P} = 81.4$ Hz), 118.4 (d, $J_{C-P} = 83.8$ Hz), 117.3 (d, $J_{C-P} = 87.4$ Hz), 115.4 (d, $J_{C-P} = 81.4$ Hz), 115.1 (d, $J_{C-P} = 79.0$ Hz), 111.7 (d, $J_{C-P} = 77.8$ Hz), 87.6, 85.6 (br), 71.3, 71.2, 68.0, 67.4, 29.5 (d, $J_{C-P} = 41.9$ Hz), 29.3 (br), 27.3 (d, $J_{C-P} = 39.5$ Hz), 18.9; ³¹P NMR (200 MHz, CDCl₃) δ 37.3, 24.1; HRMS (ESI-TOF) calcd for C₅₆H₅₀FeP₂²⁺: 420.1364 ([M]²⁺), found 420.1366.

Synthesis of BINAP-Derived Phosphonium Bromides 4 and 7.

A solution of BINAP (0.05 mmol) and benzyl bromide (0.11 mmol) in toluene (1.0 mL) was stirred for 12 h at 110 °C. The mixture was concentrated, and the residue was purified by column chromatography on silica gel (CH₂Cl₂/MeOH = 50:1-10:1 as eluent) to give mono-phosphonium bromide 7 (81% yield) and bis-phosphonium bromide 4 (19% yield).



4: $[\alpha]^{25}_{D} = 153.6 \ (c = 0.99, DMSO); {}^{1}H \ NMR \ (400 \ MHz, DMSO-d_6) \\\delta 7.98-8.23 \ (m, \ 6H), \ 7.73-7.84 \ (m, \ 2H), \ 7.66 \ (t, \ J = 7.6 \ Hz, \ 2H), \\7.54-7.62 \ (m, \ 2H), \ 7.42-7.53 \ (m, \ 4H), \ 7.24-7.38 \ (m, \ 6H), \ 6.98-7.24 \ (m, \ 12H), \ 6.78-6.97 \ (m, \ 8H), \ 4.74-5.25 \ (m, \ 4H); \ {}^{13}C \ NMR \ (125 \ MHz, \ DMSO-d_6) \\\delta 140.5 \ (d, \ J_{C-P} = 4.9 \ Hz), \ 140.4 \ (d, \ J_{C-P} = 4.8 \ Hz), \ 134.92, \ (m, \ 124-7.52)$

134.91, 134.88, 134.80, 134.5, 133.7, 133.6, 133.5, 131.4 (d, $J_{C-P} = 6.0$ Hz), 131.1 (d, $J_{C-P} = 13.1$ Hz), 130.4, 129.31, 129.27, 129.22, 129.19, 129.08, 128.7 (d, $J_{C-P} = 8.4$ Hz), 128.5 (d, $J_{C-P} = 3.6$ Hz), 127.8 (d, $J_{C-P} = 8.4$ Hz), 127.0, 116.4 (d, $J_{C-P} = 86.1$ Hz), 116.1 (d, $J_{C-P} = 83.8$ Hz), 115.3 (d, $J_{C-P} = 81.4$ Hz), 31.4 (d, $J_{C-P} = 46.8$ Hz); ³¹P NMR (200 MHz, DMSO-d₆) δ 22.6; HRMS (ESI-TOF) calcd for C₅₈H₄₆P₂²⁺: 402.1532 ([M]²⁺), found 402.1520.

7: $[a]^{25}_{D} = -60.1$ (c = 1.04, CHCl₃); ¹H NMR (400 MHz, CDCl₃) $\delta 8.18$ (dd, J = 2.8, 8.8 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.78–7.88 (m, 1H), 7.69 (t, J = 9.4 Hz, 2H), 7.11–7.57 (m, 19H), 7.08 (t, J = 7.6 Hz, 2H), 6.94–7.04 (m, 3H), 6.74–6.93 (m, 6H), 6.62–6.72 (m, 1H), 6.36 (d, J = 8.4 Hz, 1H), 4.45–4.60 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 146.65 (d, $J_{C-P} =$ 7.1 Hz), 146.58 (d, $J_{C-P} = 7.1$ Hz), 139.7 (d, $J_{C-P} = 3.6$ Hz), 139.4 (d, $J_{C-P} = 4.8$ Hz), 136.6 (d, $J_{C-P} = 14.4$ Hz), 135.3, 135.2, 134.5 (d, $J_{C-P} = 2.5$ Hz), 134.24 (d, $J_{C-P} = 3.5$ Hz), 134.16, 134.0, 133.9 (d, $J_{C-P} = 2.4$ Hz), 133.8, 133.7, 133.6, 133.3 (d, $J_{C-P} = 8.3$ Hz), 133.1 (d, $J_{C-P} = 2.4$ Hz), 133.0 (d, $J_{C-P} = 3.6$ Hz), 132.8 (d, $J_{C-P} = 6.0$ Hz), 132.6, 132.5, 132.3, 131.0 (d, $J_{C-P} = 4.8$ Hz), 129.9, 129.4, 129.3 (d, $J_{C-P} = 3.6$ Hz), 128.1, 129.0, 128.9 (d, $J_{C-P} = 13.1$ Hz), 127.5, 127.3, 127.0, 126.6 (d, $J_{C-P} = 8.4$ Hz), 125.8, 117.2 (d, $J_{C-P} = 85.0$ Hz), 116.7 (d, $J_{C-P} = 87.4$ Hz), 113.7 (d, $J_{C-P} = 85.0$ Hz), 31.3 (d, $J_{C-P} = 46.8$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 23.4, -15.4; HRMS (ESI-TOF) calcd for C₅₁H₃₉P₂⁺: 713.2522 ([M]⁺), found 713.2510.

Synthesis of Mono-Phosphonium Bromide 5.

A solution of Me-DuPHOS (0.05 mmol) and benzyl bromide (0.11 mmol) in toluene (1.0 mL) was stirred for 10 h at 110 °C. The mixture was concentrated, and the residue was purified by column chromatography on silica gel (CH₂Cl₂/MeOH = 50:1-10:1 as eluent) to give mono-phosphonium bromide **5** (90% yield).



5: $[\alpha]_{D}^{28} = 108.7$ (c = 1.03, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.93–8.05 (m, 1H), 7.81–7.89 (m, 1H), 7.66–7.80 (m, 2H), 7.15–7.37 (m, 5H), 4.58 (d, J = 14.8 Hz, 2H), 3.57–3.79 (m, 2H), 2.66–2.80 (m, 1H), 2.10–2.62 (m, 5H), 1.84–2.00 (m, 1H), 1.65–1.84 (m, 4H), 1.44–1.64 (m, 2H), 1.36 (dd, J = 7.2, 19.2 Hz, 3H), 1.18 (dd, J = 7.4, 18.2 Hz, 3H), 0.82 (dd, J = 7.2, 10.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 142.6 (dd, $J_{C-P} = 10.7$, 29.6 Hz), 137.3 (dd, $J_{C-P} = 2.5$, 11.6 Hz), 135.0 (dd, $J_{C-P} = 10.7$, 11.5 Hz), 133.7 (d, $J_{C-P} = 3.3$ Hz), 131.2 (dd, $J_{C-P} = 1.6$, 11.5 Hz), 129.94, 129.93, 129.88, 129.20, 129.17, 129.11, 128.4 (d, $J_{C-P} = 3.2$ Hz), 127.5 (dd, $J_{C-P} = 36.7$, 72.1 Hz), 40.0 (d, $J_{C-P} = 8.2$ Hz), 37.6 (d, $J_{C-P} = 2.5$ Hz), 36.9 (d, $J_{C-P} = 3.3$ Hz), 35.3 (d, $J_{C-P} = 9.9$ Hz), 33.5 (dd, $J_{C-P} = 9.1$, 48.6 Hz), 32.4 (dd, $J_{C-P} = 4.5$, 46.5 Hz), 32.2 (d, $J_{C-P} = 42.0$ Hz), 31.9 (d, $J_{C-P} = 8.2$ Hz), 31.8 (d, $J_{C-P} = 9.0$ Hz), 19.9 (d, $J_{C-P} = 3.3$ Hz), 17.0 (dd, $J_{C-P} = 3.3$, 5.0 Hz), 16.3 (d, $J_{C-P} = 3.3$ Hz), 14.3 (dd, $J_{C-P} = 3.3$, 4.9 Hz); ³¹P NMR (200 MHz, CDCl₃) δ 50.0 (d, J = 10.8 Hz), 1.4 (d, J = 11.0 Hz); HRMS (ESI-TOF) calcd for C₂₅H₃₅P₂⁺: 397.2209 ([M]⁺), found 397.2214.

General Procedure for the Synthesis of Chiral Phosphonium Bromides 6 and 8.

A solution of monophosphine (0.05 mmol) and benzyl bromide (0.06 mmol) in toluene (1.0 mL) was stirred for 10 h at 110 °C. The mixture was concentrated, and the residue was purified by column chromatography on silica gel (CH₂Cl₂/MeOH = 50:1-10:1 as eluent) to give a phosphonium bromide (93–95% yield).



6: $[\alpha]^{24}{}_{D} = -179.0 \ (c = 1.01, \text{ CHCl}_3); {}^{1}\text{H} \text{ NMR} \ (400 \text{ MHz}, \text{ CDCl}_3)$ $\delta 7.75 - 7.87 \ (m, 2\text{H}), 7.58 - 7.70 \ (m, 2\text{H}), 7.45 - 7.55 \ (m, 2\text{H}), 7.34 - 7.43 \ (m, 2\text{H}), 7.15 - 7.25 \ (m, 3\text{H}), 7.08 \ (\text{dd}, J = 1.8, 7.4 \ \text{Hz}, 1\text{H}), 6.95 - 7.04 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (\text{dd}, J = 2.8, 7.6 \ \text{Hz}, 1\text{H}), 4.44 - 4.67 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (\text{dd}, J = 2.8, 7.6 \ \text{Hz}, 1\text{H}), 4.44 - 4.67 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (\text{dd}, J = 2.8, 7.6 \ \text{Hz}, 1\text{H}), 4.44 - 4.67 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (\text{dd}, J = 2.8, 7.6 \ \text{Hz}, 1\text{H}), 4.44 - 4.67 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (\text{dd}, J = 2.8, 7.6 \ \text{Hz}, 1\text{H}), 4.44 - 4.67 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (\text{dd}, J = 2.8, 7.6 \ \text{Hz}, 1\text{H}), 4.44 - 4.67 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.40 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.80 \ (m, 2\text{H}), 6.74 - 6.84 \ (m, 1\text{H}), 6.80 \ (m, 2\text{H}), 7.6 \ (m, 2$

(m, 3H), 4.21 (dd, J = 15.0, 15.0 Hz, 1H), 3.59–3.75 (m, 2H), 2.94–3.20 (m, 3H), 2.87 (dd, J = 8.4, 16.4 Hz, 1H), 2.28 (ddd, J = 3.8, 6.6, 12.6 Hz, 2H), 1.83–2.07 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 148.1 (d, $J_{C-P} = 5.8$ Hz), 147.3 (d, $J_{C-P} = 5.8$ Hz), 145.0 (d, $J_{C-P} = 4.1$ Hz), 144.2 (d, $J_{C-P} = 3.3$ Hz), 134.4 (d, $J_{C-P} = 2.5$ Hz), 133.3 (d, $J_{C-P} = 8.3$ Hz), 130.5 (d, $J_{C-P} = 5.7$ Hz), 130.2 (d, $J_{C-P} = 6.6$ Hz), 129.7 (d, $J_{C-P} = 4.9$ Hz), 129.3 (d, $J_{C-P} = 12.3$ Hz), 129.0 (d, $J_{C-P} = 2.5$ Hz), 128.5 (d, $J_{C-P} = 3.3$ Hz), 128.1 (d, $J_{C-P} = 3.2$ Hz), 128.0 (d, $J_{C-P} = 9.1$ Hz), 127.6 (d, $J_{C-P} = 3.2$ Hz), 126.2 (d, $J_{C-P} = 4.1$ Hz), 125.4 (d, $J_{C-P} = 3.2$ Hz), 122.1 (d, $J_{C-P} = 9.1$ Hz), 121.9 (d, $J_{C-P} = 7.4$ Hz), 115.4 (d, $J_{C-P} = 79.9$ Hz), 61.8 (d, $J_{C-P} = 2.5$ Hz), 38.1, 37.8, 30.1, 30.0, 28.0 (d, $J_{C-P} = 42.8$ Hz), 24.8 (d, $J_{C-P} = 46.1$ Hz), 20.8 (d, $J_{C-P} = 46.1$ Hz); ³¹P NMR (200 MHz, CDCl₃) δ 27.1; HRMS (ESI-TOF) calcd for C₃₂H₃₀P⁺: 445.2080 ([M]⁺), found 445.2062.

Ph

$$(\alpha)^{Ph}_{OMe}$$
8: $[\alpha]^{24}_{D} = -67.0 \ (c = 1.00, \text{ CHCl}_3); ^{1}\text{H NMR (400 MHz, CDCl}_3)$
 Br^{\odot}_{OMe}
S-12

δ 8.10 (dd, J = 3.0, 9.0 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.64–7.78 (m, 3H), 7.59 (d, J = 8.4 Hz, 1H), 7.39–7.53 (m, 3H), 7.31–7.38 (m, 2H), 7.09–7.31 (m, 10H), 7.00–7.09 (m, 3H), 6.87–6.96 (m, 2H), 6.66 (d, J = 8.8 Hz, 1H), 5.07–5.23 (m, 1H), 4.70–4.85 (m, 1H), 3.62 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.5, 144.7 (d, J_{C-P} = 8.4 Hz), 135.5 (d, J_{C-P} = 2.4 Hz), 133.5 (d, J_{C-P} = 2.5 Hz), 133.34, 133.32, 133.2, 133.1, 132.9 (d, J_{C-P} = 9.6 Hz), 132.7 (d, J_{C-P} = 9.5 Hz), 132.1, 131.0 (d, J_{C-P} = 6.0 Hz), 129.8, 128.9, 128.8, 128.71, 128.66, 128.62, 128.56, 128.51, 128.3 (d, J_{C-P} = 3.6 Hz), 128.2, 128.0 (d, J_{C-P} = 3.6 Hz), 127.94, 127.85, 127.7, 127.2, 126.8 (d, J_{C-P} = 8.4 Hz), 126.6, 124.0, 123.8, 117.7 (d, J_{C-P} = 85.0 Hz), 117.5 (d, J_{C-P} = 85.6 Hz), 116.91, 116.86, 114.7 (d, J_{C-P} = 86.1 Hz), 112.0, 55.5, 30.8 (d, J_{C-P} = 46.6 Hz); ³¹P NMR (200 MHz, CDCl₃) δ 22.3; HRMS (ESI-TOF) calcd for C₄₀H₃₂OP⁺: 559.2185 ([M]⁺), found 559.2189.

General Procedure for the Catalytic Asymmetric Conjugate Addition of 3-Substituted Oxindoles.

A solution of catalyst (*S*)-91 (36 μ l, 1.4 × 10⁻³ M, 0.1 mol %) in CH₂Cl₂ was added to reaction vessel, and the solvent was completely evaporated and dried under vacuo. To the reaction vessel was added 3-substituted oxindole 10 (0.050 mmol) and mesitylene (1.0 mL), and the solution was cooled to 0 °C. To this reaction mixture was added water (1.0 mL) and acrolein (0.15 mmol), and stirred for 48 h at 0 °C. The reaction mixture was diluted with Et₂O, and organic phase was separated. The aqueous phase was extracted with Et₂O. The combined extracts were dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate as eluent) to give product 11. The enatiomeric excess of the product 11 was determined by chiral HPLC analysis. The absolute configurations of products 11 and 13 were confirmed by comparison of the optical rotations of products 11a, 11b, 13a, and 13b with the literature value.²

Ph____O

11a:² $[\alpha]^{30}{}_{D} = -66.9$ (c = 1.02, CHCl₃), HPLC analysis (90% ee): Daicel Chiralpak AD-3, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 14.9 min (major) and 20.7 min (minor). ¹H

boc NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.38 (ddd, J = 1.9, 7.1, 8.3 Hz, 1H), 7.16–7.35 (m, 7H), 2.80 (ddd, J = 4.9, 11.1, 14.6 Hz, 1H), 2.52 (ddd, J = 4.4, 11.2, 14.0 Hz, 1H), 2.33–2.46 (m, 1H), 2.15 (dddd, J = 1.1, 4.5, 11.0, 17.8 Hz, 1H), 1.63 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 200.2, 176.3, 149.1, 139.9, 139.1, 130.0, 128.9, 128.7, 127.8, 126.9, 124.8, 124.6, 115.4, 84.7, 55.8, 39.3,

30.2, 28.0; IR (neat) 2980, 2932, 1790, 1761, 1724, 1479, 1462, 1344, 1287, 1250, 1148, 841, 756, 696 cm⁻¹; HRMS (ESI-TOF) calcd for $C_{22}H_{23}NO_4Na^+$: 388.1519 ([M+Na]⁺), found 388.1505.

F Boc

HO **11b**:² $[α]^{33}_{D} = -40.7$ (*c* = 0.98, CHCl₃), HPLC analysis (88% ee): Daicel Chiralpak AD-H, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 15.0 min (major) and 16.5 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 9.66 (s, 1H), 7.95 (dd, *J* = 4.8,

9.2 Hz, 1H), 7.22–7.43 (m, 5H), 7.09 (ddd, J = 2.3, 8.9, 8.9 Hz, 1H), 6.92 (dd, J = 2.8, 8.0 Hz, 1H), 2.81 (ddd, J = 4.4, 11.0, 13.6 Hz, 1H), 2.34–2.58 (m, 2H), 2.11–2.26 (m, 1H), 1.62 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 199.9, 175.9, 160.0 (d, $J_{C-F} = 246.1$ Hz), 149.1, 138.6, 135.8 (d, $J_{C-F} = 2.5$ Hz), 132.1 (d, $J_{C-F} = 7.4$ Hz), 128.9, 128.1, 126.8, 116.8 (d, $J_{C-F} = 7.4$ Hz), 115.5 (d, $J_{C-F} = 23.1$ Hz), 112.0 (d, $J_{C-F} = 24.7$ Hz), 84.9, 56.0, 39.2, 30.0, 28.0; IR (neat) 2982, 2930, 1792, 1765, 1728, 1481, 1296, 1267, 1250, 1146, 841, 721, 696 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₂H₂₂FNO₄Na⁺: 406.1425 ([M+Na]⁺), found 406.1419.



11c: $[α]^{30}_D = -74.3$ (*c* = 1.00, CHCl₃), HPLC analysis (90% ee): Daicel Chiralpak AD-H, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 23.4 min (major) and 34.9 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 9.65 (s, 1H), 7.88 (d, *J* =

9.2 Hz, 1H), 7.19–7.43 (m, 5H), 6.90 (dd, J = 2.6, 9.0 Hz, 1H), 6.73 (d, J = 2.8 Hz, 1H), 3.80 (s, 3H), 2.81 (ddd, J = 4.4, 11.0, 13.4 Hz, 1H), 2.31–2.58 (m, 2H), 2.16 (ddd, J = 4.4, 11.4, 17.2 Hz, 1H), 1.62 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 200.3, 176.3, 157.1, 149.2, 139.2, 133.2, 131.4, 128.8, 127.8, 126.9, 116.4, 113.6, 110.8, 84.5, 56.2, 55.6, 39.3, 30.1, 28.1; IR (neat) 2980, 2934, 1788, 1759, 1724, 1487, 1296, 1277, 1248, 1152, 843, 723, 696 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₃H₂₅NO₅Na⁺: 418.1625 ([M+Na]⁺), found 418.1612.

11d: $[\alpha]_{D}^{28} = -73.4$ (*c* = 0.90, CHCl₃), HPLC analysis (90% ee): Daicel Chiralpak AD-3, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 15.3 min (major) and 20.7 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 9.65 (s, 1H), 7.81 (d, *J* = 8.4

Hz, 1H), 7.23–7.42 (m, 5H), 7.13–7.21 (m, 1H), 6.98 (d, J = 1.2 Hz, 1H), 2.80 (ddd, J = 4.6, 11.2, 13.8 Hz, 1H), 2.49 (ddd, J = 4.1, 11.6, 13.5 Hz, 1H), 2.28–2.44 (m, 4H), 2.15 (dddd, J = 1.2, 4.3, 11.1, 17.5 Hz 1H), 1.62 (s, 9H); ¹³C NMR (100 MHz, CDCl₃)

δ 200.4, 176.5, 149.2, 139.4, 137.5, 134.5, 130.1, 129.4, 128.7, 127.8, 126.9, 125.0, 115.2, 84.5, 55.9, 39.4, 30.2, 28.1, 21.1; IR (neat) 2980, 2928, 1790, 1761, 1726, 1489, 1337, 1300, 1279, 1250, 1152, 820, 721, 696 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₃H₂₅NO₄Na⁺: 402.1676 ([M+Na]⁺), found 402.1662.

The: $[\alpha]^{30}{}_{D} = -68.1 \ (c = 0.89, \text{CHCl}_3), \text{HPLC analysis (90\% ee): Daicel Chiralpak AD-3, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 11.2 min (major) and 12.9 min (minor). ¹H NMR (400 MHz, CDCl_3) & 9.64 (s, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.51-7.63 (m, 3H), 7.38-7.50 (m, 2H), 7.24-7.32 (m, 1H), 7.16-7.23$

(m, 1H), 2.81 (ddd, J = 4.9, 10.7, 13.7 Hz, 1H), 2.52 (ddd, J = 4.2, 11.2, 13.8 Hz, 1H), 2.34–2.46 (m, 1H), 2.12 (dddd, J = 1.0, 4.4, 11.0, 18.0 Hz, 1H), 1.64 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 199.8, 175.7, 148.9, 140.2, 139.9, 131.1 (q, $J_{C-F} = 32.6$ Hz), 130.6, 129.4, 129.3, 128.9, 125.1, 124.8 (q, $J_{C-F} = 3.8$ Hz), 124.6, 123.9 (q, $J_{C-F} = 273.5$ Hz), 123.7 (q, $J_{C-F} = 3.8$ Hz), 115.7, 85.0, 55.6, 39.2, 30.6, 28.0; IR (neat) 2982, 2930, 1790, 1761, 1728, 1479, 1327, 1287, 1250, 1148, 1125, 841, 756, 700 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₃H₂₂F₃NO₄Na⁺: 456.1393 ([M+Na]⁺), found 456.1393.



11f: $[\alpha]^{31}{}_{D} = -71.1$ (c = 0.93, CHCl₃), HPLC analysis (91% ee): Daicel CHO Chiralpak AD-3, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 14.3 min (major) and 17.8 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.37–7.46 (m, 1H), 7.22–7.35 (m, 2H), 7.17–7.22 (m, 1H), 7.09–7.16

(m, 1H), 7.03 (ddd, J = 2.1, 2.1, 10.5 Hz, 1H), 6.93–7.01 (m, 1H), 2.77 (ddd, J = 4.7, 10.9, 13.7 Hz, 1H), 2.51 (ddd, J = 4.4, 11.4, 13.8, 1H), 2.32–2.45 (m, 1H), 2.06–2.21 (m, 1H), 1.63 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 200.0, 175.8, 162.9 (d, $J_{C-F} = 247.8$ Hz), 149.0, 141.6 (d, $J_{C-F} = 6.6$ Hz), 139.9, 130.2 (d, $J_{C-F} = 9.1$ Hz), 129.3, 129.2, 124.9, 124.6, 122.7 (d, $J_{C-F} = 2.5$ Hz), 115.5, 114.8 (d, $J_{C-F} = 20.6$ Hz), 114.4 (d, $J_{C-F} = 23.8$ Hz), 84.9, 55.6, 39.2, 30.3, 28.0; IR (neat) 2980, 2930, 1790, 1761, 1726, 1481, 1464, 1344, 1287, 1250, 1148, 839, 756 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₂H₂₂FNO₄Na⁺: 406.1425 ([M+Na]⁺), found 406.1413.



11g: $[\alpha]^{31}{}_{D} = -70.9$ (*c* = 0.93, CHCl₃), HPLC analysis (91% ee): Daicel Chiralpak AD-3, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 15.5 min (major) and 19.5 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 7.95 (d, *J* = 8.0 Hz, 1H),

7.36–7.47 (m, 1H), 7.21–7.36 (m, 3H), 7.14–7.21 (m, 1H), 6.94–7.06 (m, 2H), 2.77 (ddd, J = 3.8, 11.0, 13.6 Hz, 1H), 2.49 (ddd, J = 4.2, 11.0, 13.6, 1H), 2.31–2.44 (m, 1H), 2.03–2.21 (m, 1H), 1.63 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 200.1, 176.2, 162.3 (d, $J_{C-F} = 248.6$ Hz), 149.0, 139.9, 134.9 (d, $J_{C-F} = 2.4$ Hz), 129.6, 129.1, 128.8 (d, $J_{C-F} = 8.3$ Hz), 124.9, 124.6, 115.6 (d, $J_{C-F} = 21.4$ Hz), 115.5, 84.8, 55.2, 39.3, 30.5, 28.0; IR (neat) 2980, 2928, 1790, 1763, 1728, 1508, 1344, 1287, 1250, 1150, 841, 756 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₂H₂₂FNO₄Na⁺: 406.1425 ([M+Na]⁺), found 406.1418.



11h: $[\alpha]^{30}{}_{D} = -52.7$ (*c* = 0.96, CHCl₃), HPLC analysis (88% ee): Daicel Chiralpak AD-H, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 15.5 min (major) and 21.3 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 9.64 (t, *J* = 1.0 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.37 (ddd, *J* = 1.8, 7.2, 8.4 Hz, 1H), 7.16–7.25 (m, 4H), 7.07–7.15

(m, 2H), 2.78 (ddd, J = 4.8, 11.0, 13.8 Hz, 1H), 2.50 (ddd, J = 4.6, 11.2, 13.8 Hz, 1H), 2.24–2.44 (m, 4H), 2.14 (dddd, J = 1.3, 4.5, 11.1, 17.9 Hz, 1H), 1.62 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 200.3, 176.4, 149.2, 139.9, 137.6, 136.2, 130.2, 129.5, 128.8, 126.8, 124.8, 124.6, 115.4, 84.6, 55.5, 39.4, 30.2, 28.1, 20.9; IR (neat) 2980, 2930, 1792, 1763, 1726, 1479, 1344, 1287, 1250, 1148, 841, 756 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₃H₂₅NO₄Na⁺: 402.1676 ([M+Na]⁺), found 402.1668.



11i: $[\alpha]^{28}{}_{D} = -26.1$ (*c* = 0.98, CHCl₃), HPLC analysis (91% ee): Daicel Chiralpak AD-H, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 22.8 min (major) and 29.1 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 9.67 (s, 1H), 7.99 (d, *J* = 8.0 Hz, 1H), 7.70–7.84 (m, 4H), 7.37–7.53 (m, 4H), 7.21–7.33 (m, 2H), 2.93 (ddd, *J* = 4.9, 11.1, 13.9 Hz, 1H), 2.63 (ddd, *J* = 4.7, 11.3, 14.1 Hz, 1H),

2.38–2.53 (m, 1H), 2.14–2.28 (m, 1H), 1.63 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 200.3, 176.3, 149.2, 139.9, 136.5, 133.1, 132.7, 130.1, 129.0, 128.7, 128.2, 127.4, 126.4, 126.3, 126.0, 124.9, 124.69, 124.68, 115.5, 84.7, 56.0, 39.4, 30.1, 28.1; IR (neat) 2980, 2932, 1788, 1761, 1724, 1479, 1342, 1287, 1250, 1146, 816, 754 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₆H₂₅NO₄Na⁺: 438.1676 ([M+Na]⁺), found 438.1681.



13a:² $[\alpha]^{32}{}_{\rm D} = -44.3$ (*c* = 1.10, CHCl₃), HPLC analysis (90% ee): Daicel Chiralpak AD-H, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 14.9 min (major) and 21.3 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, *J* = 8.0 Hz, 1H), 7.35–7.42 (m, 1H),

7.15–7.34 (m, 7H), 2.75 (ddd, J = 4.5, 11.3, 13.7 Hz, 1H), 2.49 (ddd, J = 4.2, 11.6, 13.8 Hz, 1H), 2.29–2.42 (m, 1H), 2.03–2.13 (m, 1H), 2.01, (s, 3H), 1.63 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 207.0, 176.5, 149.2, 139.8, 139.4, 130.4, 128.7, 127.7, 126.9, 124.74, 124.71, 115.3, 84.6, 55.9, 38.7, 31.7, 29.9, 28.1; IR (neat) 2980, 2928, 1790, 1763, 1728, 1479, 1464, 1346, 1288, 1250, 1148, 841, 758, 696 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₃H₂₅NO₄Na⁺: 402.1676 ([M+Na]⁺), found 402.1669.



13b:² $[\alpha]^{29}{}_{D} = -43.8$ (*c* = 1.00, CHCl₃), HPLC analysis (90% ee): Daicel Chiralpak AD-H, hexane/2-propanol = 20:1, flow rate = 0.5 mL/min, 224 nm; retention time: 14.5 min (major) and 19.7 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 8.4 Hz, 1H), 7.34–7.44 (m, 1H), 7.15–7.34 (m, 7H), 2.75 (ddd, *J* = 5.1, 11.1, 14.1

Hz, 1H), 2.52 (ddd, J = 4.6, 11.4, 14.2 Hz, 1H), 2.14–2.40 (m, 3H), 2.04 (ddd, J = 4.9, 11.3, 17.1 Hz, 1H), 1.63 (s, 9H), 0.95 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 209.7, 176.5, 149.2, 139.8, 139.5, 130.4, 128.69, 128.68, 127.7, 126.9 124.8, 124.7, 115.3, 84.6, 56.0, 37.4, 35.9, 31.8, 28.1, 7.6; IR (neat) 2978, 2936, 1792, 1763, 1728, 1479, 1462, 1346, 1288, 1250, 1148, 841, 758, 696 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₄H₂₇NO₄Na⁺: 416.1832 ([M+Na]⁺), found 416.1821.

Typical Procedure for the Catalytic Asymmetric Sulfenylation of 3-Substituted Oxindole.

To a solution of catalyst **9h** (0.00050 mmol) and 3-aryloxindole **10h** (0.050 mmol) in *o*-xylene (1.0 mL) was added *N*-(arylthio)phthalimide (0.060 mmol) and water (1.0 mL) at 0 °C. After stirring for 48 h at 0 °C, the reaction mixture was diluted with ethyl acetate and organic phase was separated. The aqueous phase was extracted with ethyl acetate. The combined extracts were dried over Na_2SO_4 and concentrated. The residue was purified by preparative thin layer chromatography on silica gel (hexane/ethyl acetate as eluent) to give product **14**. The enatiomeric excess of the product **14** was determined by chiral HPLC analysis.



14: $[\alpha]^{26}_{D} = 106.1$ (*c* = 0.97, CHCl₃), HPLC analysis (80% ee): Daicel Chiralcel OD-H, hexane/2-propanol = 40:1, flow rate = 0.5 mL/min, 224 nm; retention time: 8.7 min (major) and 11.9 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.53–7.64 (m, 3H), 7.42–7.49 (m, 1H), 7.22–7.31 (m, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 7.01–7.09 (m, 1H), 6.96

(ddd, J = 1.1, 2.5, 8.5 Hz, 1H), 6.87–6.94 (m, 2H), 2.35 (s, 3H), 1.55 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 173.2, 161.8 (d, $J_{C-F} = 251.0$ Hz), 148.6, 139.3, 138.6, 132.3, 132.1 (d, $J_{C-F} = 3.2$ Hz), 131.4 (d, $J_{C-F} = 8.2$ Hz), 129.5 (d, $J_{C-F} = 9.1$ Hz), 129.4, 129.2, 128.4, 128.2, 126.2, 124.6, 123.1 (d, $J_{C-F} = 22.2$ Hz), 116.8 (d, $J_{C-F} = 20.6$ Hz), 114.7, 84.3, 62.6, 27.9, 21.1; IR (neat) 1764, 1733, 1476, 1466, 1343, 1301, 1290, 1250, 1216, 1148, 1093, 880, 752 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₆H₂₄FNO₃SNa⁺: 472.1353 ([M+Na]⁺), found 472.1365.

The absolute configuration of product 14 was confirmed by comparison of the optical rotation of related compound 14' with the literature value.³ The product 14' was synthesized by the above-mentioned method.



14':³ $[\alpha]^{30}{}_{D} = 88.0 \ (c = 1.14, CHCl_3; 74\% ee) [lit.³ <math>[\alpha]^{22}{}_{D} = -173.7 \ (c = 1.0, CHCl_3; 97\%$ ee for (*R*))], HPLC analysis (74% ee): Daicel Chiralcel OD-H, hexane/2-propanol = 98:2, flow rate = 1.0 mL/min, 224 nm; retention time: 4.7 min (major) and 5.9 min (minor). [lit.³ Daicel Chiralcel OD-H, hexane/2-propanol = 98:2, flow rate = 1.0 mL/min, 210 nm; retention time: 5.1 min (*S*) and 7.5 min (*R*)]. ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.61 (m, 3H), 7.39–7.46 (m, 1H), 7.21–7.25 (m, 3H), 7.18 (d, *J* = 8.4 Hz, 2H), 7.11–7.16 (m, 2H), 7.04–7.11 (m, 2H), 2.34 (s, 3H), 1.53 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 148.6, 139.3, 138.4, 136.5, 132.6, 129.7, 129.5, 129.3, 128.9, 128.8, 128.33, 128.27, 126.2, 124.4, 114.7, 84.0, 62.6, 28.0, 21.1; IR (neat) 1764, 1731, 1477, 1466, 1343, 1301, 1290, 1250, 1148, 1092, 752 cm⁻¹; HRMS (ESI-TOF) calcd for C₂₆H₂₅NO₃SNa⁺: 454.1447 ([M+Na]⁺), found 454.1447.

References

- (a) T. Hayashi, J. Organomet. Chem., 1999, 576, 195; (b) T. Hayashi, Acc. Chem. Res., 2000, 33, 354; (c) Y. Uozumi, M. Kawatsura and T. Hayashi, Org. Synth., 2002, 78, 1.
- 2. R. He, C. Ding and K. Maruoka, Angew. Chem., Int. Ed., 2009, 48, 4559.
- 3. X. Li, C. Liu, X.-S. Xue and J.-P. Cheng, Org. Lett., 2012, 14, 4374.

























































































